Predictive Molecular Diagnostics Unit

Unit

Clinical activity

The Predictive Molecular Diagnostics Unit, part of the Pathology Unit, performs genomic tests (gene sequencing, in situ hybridizations, gene expression profiles, predictive immunohistochemical dosages) on tumor tissues to assist oncologists in choosing the best treatment for patients with cancer.

Studying the genetic alterations of tumors is a practice that has become essential since the introduction of the so-called “target drugs” (antibodies and inhibitory molecules), capable of attacking neoplastic cells in a specific way. Furthermore, in recent years, the introduction of antineoplastic immunotherapics has broadened the therapeutic targets and introduced new predictive molecular response markers.

The Predictive Molecular Diagnostics Unit has the most advanced technological instruments and uses only certified and validated diagnostic kits. In addition, the laboratory constantly undergoes Italian and European quality controls.

The range of tests available is continuously updated based on the drugs authorized in Italy by AIFA (the Italian Drug Agency).

Each test is available through the NHS. Multiple tests can be performed on the same sample, and for each of them a separate NHS prescription is required. Complete genetic panels are also available through Private Health Care.

Available tumor tests

Neoplasia Sequencing /GEP FISH
Colorectal carcinoma KRAS
NRAS
BRAF
MSI – microsatellite instability
(HER2)*
Lung carcinoma (NSCLC) EGFR
BRAF
ALK – FISH and immunohistochemestry
ROS1
(c-MET)*
PD-L1 – Immunohistochemestry
Liquid biopsy (ctDNA in NSCLC) ct-EGFR
Breast carcinoma PROSIGNA** (currently not available)
ONCOTYPE**
HER2
Melanoma BRAF
NRAS
c-KIT – acral e mucosal melanoma
Ovarian carcinoma BRCA 1
BRCA 2
Prostate carcinoma BRCA 1
BRCA 2
Gastric carcinoma HER2
GIST c-KIT
PDGFRA
BRAF
Thyroid carcinoma BRAF
KRAS
NRAS
HRAS
Urinary bladder carcinoma Urovysion – urinary sediment cytology
Soft tissues EWSR1 – Ewing sarcoma
DDIT3 – myxoid liposarcoma
MDM2 – DD liposarcoma
Hematological tumors BCL2/IGH
BCL2/Break Apart
C-MYC
BCL6
CCND1

* markers for inclusion in specific clinical trials.
**“Genomic Profiling” tests not refundable from Regional Health System (SSR) but available upon payment. For further information on the availability of test, see the link above.

All benefits are payable through NHS and through private health care (available also for private institutions and medical clinics).

The acceptance of the material is carried out by the Acceptance Service of the Campus Bio-Medico University Hospital, from Monday to Friday, h 7.30 am – 12.30 pm and 2.30 – 4.00 pm.